Abstract
In chronic arthritis synovial inflammation is usually accompanied by bone erosion. Due to resulting structural damage, bone erosion is major reason for disability of RA patients. Thus, drug therapy in arthritis is not only focussed on the control of synovial inflammation but also on preserving bone from structural damage. Bone erosion in arthritis is a consequence of synovial osteoclast formation. Therapeutic approaches, which interfere with synovial osteoclastogenesis and/or osteoclast activation, are therefore of great interest. This review describes the pathomechanism of arthritic bone erosion, describes its cellular and molecular players and gives insights in current therapeutic tools to inhibit this process. Effects of blockade of tumor necrosis factor, interleukin-1 and receptor activator of NF-kB ligand are discussed. Arthritis and bone loss are two related conditions but they are not necessarily linked to each other. Thus, in case of shortlasting and self-limited disease, structural damage is highly unusual. One of the most intriguing examples is viral arthritis, which as in case of parvovirus infection is a polyarticular disease closely mimicking rheumatoid arthritis. However, parvoviral arthritis is always a self-limited condition and resolves without any structural damage. In contrast, chronic forms of arthritis, such as psoriatic arthritis or rheumatoid arthritis (RA) are usually destructive and lead to alteration of joint structure and functional impairment.
Keywords: bone erosion, disease modifying antirheumatic drug (dmard), chrondroclasts, tartrate-resistant phosphatase (trap), osteoclastogenesis, rankl expression
Current Pharmaceutical Design
Title: New Insights in the Mechanism of Bone Loss in Arthritis
Volume: 11 Issue: 23
Author(s): G. Schett and J. S. Smolen
Affiliation:
Keywords: bone erosion, disease modifying antirheumatic drug (dmard), chrondroclasts, tartrate-resistant phosphatase (trap), osteoclastogenesis, rankl expression
Abstract: In chronic arthritis synovial inflammation is usually accompanied by bone erosion. Due to resulting structural damage, bone erosion is major reason for disability of RA patients. Thus, drug therapy in arthritis is not only focussed on the control of synovial inflammation but also on preserving bone from structural damage. Bone erosion in arthritis is a consequence of synovial osteoclast formation. Therapeutic approaches, which interfere with synovial osteoclastogenesis and/or osteoclast activation, are therefore of great interest. This review describes the pathomechanism of arthritic bone erosion, describes its cellular and molecular players and gives insights in current therapeutic tools to inhibit this process. Effects of blockade of tumor necrosis factor, interleukin-1 and receptor activator of NF-kB ligand are discussed. Arthritis and bone loss are two related conditions but they are not necessarily linked to each other. Thus, in case of shortlasting and self-limited disease, structural damage is highly unusual. One of the most intriguing examples is viral arthritis, which as in case of parvovirus infection is a polyarticular disease closely mimicking rheumatoid arthritis. However, parvoviral arthritis is always a self-limited condition and resolves without any structural damage. In contrast, chronic forms of arthritis, such as psoriatic arthritis or rheumatoid arthritis (RA) are usually destructive and lead to alteration of joint structure and functional impairment.
Export Options
About this article
Cite this article as:
Schett G. and Smolen S. J., New Insights in the Mechanism of Bone Loss in Arthritis, Current Pharmaceutical Design 2005; 11 (23) . https://dx.doi.org/10.2174/1381612054865046
DOI https://dx.doi.org/10.2174/1381612054865046 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Using Alendronic Acid Coupled Fluorescently Labelled SM Liposomes as a Vehicle for Bone Targeting
Current Pharmaceutical Design Osteoarthritis: Is there a Window of Opportunity
Current Rheumatology Reviews Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets The Role of Heme Oxygenase-1 in T Cell-Mediated Immunity: The All Encompassing Enzyme
Current Pharmaceutical Design Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Multiple Roles for Chemokines in the Pathogenesis of SIV Infection
Current HIV Research The Role of Autophagy in Rheumatic Disease
Current Drug Targets The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Parallel Gene Expression Profiling of Mantle Cell Lymphoma – How Do We Transform ´Omics Data into Clinical Practice
Current Genomics Meet Our Editorial Board Member
Current Medicinal Chemistry Ethanol and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Studies on Growth Kinetics of Serratia marcescens VITSD2 and Optimization of Fermentation Conditions for Serratiopeptidase Production
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Serological Electrodetection of Rheumatoid Arthritis Using Mimetic Peptide
Protein & Peptide Letters Microglia-Targeted Pharmacotherapy in Retinal Neurodegenerative Diseases
Current Drug Targets VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?
Current Pharmaceutical Design Editorial
Current Rheumatology Reviews Small Molecule Inhibitors of Lck: The Search for Specificity within a Kinase Family
Mini-Reviews in Medicinal Chemistry Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (β-D-mannuronic Acid) as a Novel NSAID with Immunosuppressive Property
Endocrine, Metabolic & Immune Disorders - Drug Targets Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmunity in Type 1 Diabetes
Current Stem Cell Research & Therapy